Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?
- 1 July 2004
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 86 (2) , 181-189
- https://doi.org/10.1023/b:brea.0000032986.00879.d7
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals of Oncology, 1999
- Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancerBritish Journal of Cancer, 1998
- Prognosis and prediction of response in breast cancer: the current role of the main biological markersCell Proliferation, 1998
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piBritish Journal of Cancer, 1996
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancerAnnals of Oncology, 1994
- Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility studyBritish Journal of Cancer, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- The p53 tumour suppressor geneNature, 1991
- Reporting results of cancer treatmentCancer, 1981